25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

SYRE (Spyre) Stock Analysis
Buy, Hold or Sell?

Let's analyze Spyre together

I guess you are interested in Spyre Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Spyre’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Spyre’s Price Targets

I'm going to help you getting a better view of Spyre Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Spyre Therapeutics Inc.

I send you an email if I find something interesting about Spyre Therapeutics Inc..

1. Quick Overview

1.1. Quick analysis of Spyre (30 sec.)










1.2. What can you expect buying and holding a share of Spyre? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.51
Expected worth in 1 year
$8.82
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$1.31
Return On Investment
6.2%

For what price can you sell your share?

Current Price per Share
$21.17
Expected price per share
$19.20 - $20.33
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Spyre (5 min.)




Live pricePrice per Share (EOD)
$21.17
Intrinsic Value Per Share
$-35.48 - $-21.94
Total Value Per Share
$-27.97 - $-14.44

2.2. Growth of Spyre (5 min.)




Is Spyre growing?

Current yearPrevious yearGrowGrow %
How rich?$455.7m$116.3m$329.5m73.9%

How much money is Spyre making?

Current yearPrevious yearGrowGrow %
Making money-$51.7m-$46.4m-$5.2m-10.1%
Net Profit Margin0.0%-1,515.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Spyre (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Spyre?

Welcome investor! Spyre's management wants to use your money to grow the business. In return you get a share of Spyre.

First you should know what it really means to hold a share of Spyre. And how you can make/lose money.

Speculation

The Price per Share of Spyre is $21.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Spyre.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Spyre, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.51. Based on the TTM, the Book Value Change Per Share is $0.33 per quarter. Based on the YOY, the Book Value Change Per Share is $2.41 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Spyre.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.60-2.9%-0.86-4.0%-0.77-3.6%-0.92-4.3%-0.68-3.2%-0.43-2.0%
Usd Book Value Change Per Share-0.48-2.3%0.331.5%2.4111.4%0.512.4%0.251.2%0.170.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.48-2.3%0.331.5%2.4111.4%0.512.4%0.251.2%0.170.8%
Usd Price Per Share14.97-20.95-23.80-15.06-11.30-8.63-
Price to Earnings Ratio-6.19--6.08--7.99--4.78--5.08--7.01-
Price-to-Total Gains Ratio-31.12--22.31--20.55--14.67--11.85--15.43-
Price to Book Ratio1.99-3.04-5.72-3.04-3.06-4.21-
Price-to-Total Gains Ratio-31.12--22.31--20.55--14.67--11.85--15.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.17
Number of shares47
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.330.25
Usd Total Gains Per Share0.330.25
Gains per Quarter (47 shares)15.4011.72
Gains per Year (47 shares)61.6046.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10625204737
2012311409484
301851760141131
402462380188178
503083000234225
603703620281272
704314240328319
804934860375366
905545480422413
1006166100469460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.043.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.029.00.027.5%13.030.00.030.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.043.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%11.029.00.027.5%13.030.00.030.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Spyre Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.4810.328-247%2.408-120%0.510-194%0.249-293%0.170-383%
Book Value Per Share--7.5097.373+2%1.926+290%3.023+148%2.518+198%1.812+314%
Current Ratio--6.4878.281-22%11.587-44%7.743-16%7.225-10%9.434-31%
Debt To Asset Ratio--0.1540.170-9%0.869-82%0.577-73%0.426-64%0.271-43%
Debt To Equity Ratio--0.1820.206-12%0.806-77%0.448-59%0.371-51%0.256-29%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1352148353.5001704958794.625-21%1549191552.500-13%1084081992.125+25%822209862.525+64%668556465.149+102%
Eps---0.605-0.855+41%-0.770+27%-0.918+52%-0.678+12%-0.429-29%
Ev To Ebitda Ratio---6.509-7.645+17%-8.580+32%-5.474-16%-6.159-5%-8.848+36%
Free Cash Flow Per Share---0.767-0.637-17%-0.647-16%-0.521-32%-0.427-44%-0.293-62%
Free Cash Flow To Equity Per Share---0.7550.353-314%0.692-209%0.545-239%0.270-379%0.185-509%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.945----------
Intrinsic Value_10Y_min---35.476----------
Intrinsic Value_1Y_max---1.323----------
Intrinsic Value_1Y_min---2.350----------
Intrinsic Value_3Y_max---4.642----------
Intrinsic Value_3Y_min---8.146----------
Intrinsic Value_5Y_max---8.767----------
Intrinsic Value_5Y_min---15.088----------
Market Cap1278689170.000+29%908627353.5001266431544.625-28%1437694802.500-37%910017825.4580%682954862.525+33%521110005.263+74%
Net Profit Margin----0%-15.1580%-57.1690%-38.0160%-20.3970%
Operating Margin----0%-11.4050%-33.6870%-23.9340%-13.3740%
Operating Ratio----0%11.247-100%50.538-100%34.357-100%18.886-100%
Pb Ratio2.819+29%1.9943.039-34%5.722-65%3.037-34%3.056-35%4.215-53%
Pe Ratio-8.749-41%-6.187-6.077-2%-7.989+29%-4.777-23%-5.082-18%-7.012+13%
Price Per Share21.170+29%14.97020.949-29%23.803-37%15.060-1%11.303+32%8.626+74%
Price To Free Cash Flow Ratio-6.899-41%-4.878-8.842+81%-10.397+113%-6.543+34%-2.909-40%-6.608+35%
Price To Total Gains Ratio-44.007-41%-31.119-22.306-28%-20.550-34%-14.673-53%-11.846-62%-15.431-50%
Quick Ratio--11.73915.212-23%19.042-38%12.732-8%11.607+1%13.833-15%
Return On Assets---0.068-0.101+48%-0.139+104%-0.222+226%-0.196+188%-0.168+147%
Return On Equity---0.081-0.123+53%-0.184+128%-0.202+150%-0.201+150%-0.184+128%
Total Gains Per Share---0.4810.328-247%2.408-120%0.510-194%0.249-293%0.170-383%
Usd Book Value--455773000.000445894250.000+2%116317000.000+292%182749000.000+149%152185450.000+199%109530125.000+316%
Usd Book Value Change Per Share---0.4810.328-247%2.408-120%0.510-194%0.249-293%0.170-383%
Usd Book Value Per Share--7.5097.373+2%1.926+290%3.023+148%2.518+198%1.812+314%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--1352148353.5001704958794.625-21%1549191552.500-13%1084081992.125+25%822209862.525+64%668556465.149+102%
Usd Eps---0.605-0.855+41%-0.770+27%-0.918+52%-0.678+12%-0.429-29%
Usd Free Cash Flow---46563000.000-38544250.000-17%-39105750.000-16%-31507166.667-32%-25779100.000-45%-17707650.000-62%
Usd Free Cash Flow Per Share---0.767-0.637-17%-0.647-16%-0.521-32%-0.427-44%-0.293-62%
Usd Free Cash Flow To Equity Per Share---0.7550.353-314%0.692-209%0.545-239%0.270-379%0.185-509%
Usd Market Cap1278689170.000+29%908627353.5001266431544.625-28%1437694802.500-37%910017825.4580%682954862.525+33%521110005.263+74%
Usd Price Per Share21.170+29%14.97020.949-29%23.803-37%15.060-1%11.303+32%8.626+74%
Usd Profit---36717000.000-51703500.000+41%-46495250.000+27%-55446166.667+51%-40933050.000+11%-25943575.000-29%
Usd Revenue----0%260500.000-100%189166.667-100%1149800.000-100%984350.000-100%
Usd Total Gains Per Share---0.4810.328-247%2.408-120%0.510-194%0.249-293%0.170-383%
 EOD+5 -3MRQTTM+14 -18YOY+14 -203Y+16 -185Y+20 -1410Y+15 -19

3.3 Fundamental Score

Let's check the fundamental score of Spyre Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.749
Price to Book Ratio (EOD)Between0-12.819
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.739
Current Ratio (MRQ)Greater than16.487
Debt to Asset Ratio (MRQ)Less than10.154
Debt to Equity Ratio (MRQ)Less than10.182
Return on Equity (MRQ)Greater than0.15-0.081
Return on Assets (MRQ)Greater than0.05-0.068
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Spyre Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5072.848
Ma 20Greater thanMa 5016.186
Ma 50Greater thanMa 10016.388
Ma 100Greater thanMa 20016.248
OpenGreater thanClose17.660
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2025-09-19 02:08:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Spyre earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Spyre to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Spyre Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,515.8%+1,515.8%
TTM-5Y-3,801.6%+3,801.6%
5Y-3,801.6%10Y-2,039.7%-1,761.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--68.9%+68.9%
TTM--157.5%+157.5%
YOY-1,515.8%-189.1%-1,326.7%
3Y-5,716.9%-262.3%-5,454.6%
5Y-3,801.6%-336.5%-3,465.1%
10Y-2,039.7%-471.4%-1,568.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Spyre is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Spyre to theΒ Biotechnology industry mean.
  • -6.8% Return on Assets means thatΒ Spyre generatedΒ $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Spyre Therapeutics Inc.:

  • The MRQ is -6.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.8%TTM-10.1%+3.3%
TTM-10.1%YOY-13.9%+3.9%
TTM-10.1%5Y-19.6%+9.6%
5Y-19.6%10Y-16.8%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.8%-11.9%+5.1%
TTM-10.1%-11.8%+1.7%
YOY-13.9%-11.1%-2.8%
3Y-22.2%-12.0%-10.2%
5Y-19.6%-11.8%-7.8%
10Y-16.8%-13.9%-2.9%
4.3.1.3. Return on Equity

Shows how efficient Spyre is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Spyre to theΒ Biotechnology industry mean.
  • -8.1% Return on Equity means Spyre generated $-0.08Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Spyre Therapeutics Inc.:

  • The MRQ is -8.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.1%TTM-12.3%+4.3%
TTM-12.3%YOY-18.4%+6.1%
TTM-12.3%5Y-20.1%+7.8%
5Y-20.1%10Y-18.4%-1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.1%-14.1%+6.0%
TTM-12.3%-14.7%+2.4%
YOY-18.4%-15.3%-3.1%
3Y-20.2%-16.7%-3.5%
5Y-20.1%-17.1%-3.0%
10Y-18.4%-19.7%+1.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Spyre Therapeutics Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Spyre is operatingΒ .

  • Measures how much profit Spyre makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Spyre to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Spyre Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,140.5%+1,140.5%
TTM-5Y-2,393.4%+2,393.4%
5Y-2,393.4%10Y-1,337.4%-1,056.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--153.1%+153.1%
TTM--265.6%+265.6%
YOY-1,140.5%-242.6%-897.9%
3Y-3,368.7%-247.2%-3,121.5%
5Y-2,393.4%-326.3%-2,067.1%
10Y-1,337.4%-487.4%-850.0%
4.3.2.2. Operating Ratio

Measures how efficient Spyre is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Spyre Therapeutics Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY11.247-11.247
TTM-5Y34.357-34.357
5Y34.35710Y18.886+15.471
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.861-1.861
TTM-2.729-2.729
YOY11.2472.820+8.427
3Y50.5383.542+46.996
5Y34.3574.614+29.743
10Y18.8866.171+12.715
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Spyre Therapeutics Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Spyre is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 6.49Β means the company has $6.49 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Spyre Therapeutics Inc.:

  • The MRQ is 6.487. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.281. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.487TTM8.281-1.793
TTM8.281YOY11.587-3.306
TTM8.2815Y7.225+1.056
5Y7.22510Y9.434-2.209
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4873.414+3.073
TTM8.2813.605+4.676
YOY11.5874.048+7.539
3Y7.7434.419+3.324
5Y7.2255.731+1.494
10Y9.4346.121+3.313
4.4.3.2. Quick Ratio

Measures if Spyre is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Spyre to theΒ Biotechnology industry mean.
  • A Quick Ratio of 11.74Β means the company can pay off $11.74 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Spyre Therapeutics Inc.:

  • The MRQ is 11.739. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.212. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.739TTM15.212-3.473
TTM15.212YOY19.042-3.830
TTM15.2125Y11.607+3.604
5Y11.60710Y13.833-2.225
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7392.783+8.956
TTM15.2123.128+12.084
YOY19.0423.806+15.236
3Y12.7324.322+8.410
5Y11.6075.680+5.927
10Y13.8336.495+7.338
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Spyre Therapeutics Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of SpyreΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Spyre to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15Β means that Spyre assets areΒ financed with 15.4% credit (debt) and the remaining percentage (100% - 15.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Spyre Therapeutics Inc.:

  • The MRQ is 0.154. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.170. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.154TTM0.170-0.016
TTM0.170YOY0.869-0.699
TTM0.1705Y0.426-0.257
5Y0.42610Y0.271+0.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1540.346-0.192
TTM0.1700.364-0.194
YOY0.8690.337+0.532
3Y0.5770.350+0.227
5Y0.4260.349+0.077
10Y0.2710.380-0.109
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Spyre is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Spyre to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 18.2% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Spyre Therapeutics Inc.:

  • The MRQ is 0.182. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.206. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.182TTM0.206-0.024
TTM0.206YOY0.806-0.600
TTM0.2065Y0.371-0.165
5Y0.37110Y0.256+0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1820.402-0.220
TTM0.2060.448-0.242
YOY0.8060.436+0.370
3Y0.4480.471-0.023
5Y0.3710.469-0.098
10Y0.2560.517-0.261
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Spyre generates.

  • Above 15 is considered overpriced butΒ always compareΒ Spyre to theΒ Biotechnology industry mean.
  • A PE ratio of -6.19 means the investor is paying $-6.19Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Spyre Therapeutics Inc.:

  • The EOD is -8.749. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.187. Based on the earnings, the company is expensive. -2
  • The TTM is -6.077. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.749MRQ-6.187-2.562
MRQ-6.187TTM-6.077-0.110
TTM-6.077YOY-7.989+1.912
TTM-6.0775Y-5.082-0.995
5Y-5.08210Y-7.012+1.930
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.749-2.952-5.797
MRQ-6.187-2.328-3.859
TTM-6.077-2.657-3.420
YOY-7.989-3.622-4.367
3Y-4.777-3.737-1.040
5Y-5.082-5.857+0.775
10Y-7.012-6.949-0.063
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Spyre Therapeutics Inc.:

  • The EOD is -6.899. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.878. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.842. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.899MRQ-4.878-2.020
MRQ-4.878TTM-8.842+3.963
TTM-8.842YOY-10.397+1.555
TTM-8.8425Y-2.909-5.932
5Y-2.90910Y-6.608+3.699
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.899-3.656-3.243
MRQ-4.878-2.911-1.967
TTM-8.842-3.682-5.160
YOY-10.397-4.243-6.154
3Y-6.543-5.190-1.353
5Y-2.909-8.391+5.482
10Y-6.608-9.883+3.275
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Spyre is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.99 means the investor is paying $1.99Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Spyre Therapeutics Inc.:

  • The EOD is 2.819. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.994. Based on the equity, the company is underpriced. +1
  • The TTM is 3.039. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.819MRQ1.994+0.826
MRQ1.994TTM3.039-1.045
TTM3.039YOY5.722-2.683
TTM3.0395Y3.056-0.017
5Y3.05610Y4.215-1.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8192.519+0.300
MRQ1.9942.059-0.065
TTM3.0392.220+0.819
YOY5.7222.464+3.258
3Y3.0372.641+0.396
5Y3.0563.760-0.704
10Y4.2154.482-0.267
4.6.2. Total Gains per Share

2.4. Latest News of Spyre Therapeutics Inc.

Does Spyre Therapeutics Inc. still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Spyre Therapeutics Inc. to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-10-05
15:00
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025Read
2025-10-03
22:05
Spyre Therapeutics Announces Grants of Inducement AwardsRead
2025-09-15
19:51
Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 TrialRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Spyre Therapeutics Inc..

4.8.3. Insider Transactions

Insiders are holding 8.705% of the shares of Spyre Therapeutics Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-09-02Scott L BurrowsSELL1842816.26
2024-10-25Jeffrey W AlbersSELL30036.43
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets538,832
Total Liabilities83,059
Total Stockholder Equity455,773
 As reported
Total Liabilities 83,059
Total Stockholder Equity+ 455,773
Total Assets = 538,832

Assets

Total Assets538,832
Total Current Assets538,832
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 81,659
Short-term Investments 444,921
Net Receivables 3,500
Other Current Assets 8,752
Total Current Assets  (as reported)538,832
Total Current Assets  (calculated)538,832
+/- 0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities83,059
Long-term Liabilities0
Total Stockholder Equity455,773
Total Current Liabilities
Accounts payable 3,712
Other Current Liabilities 79,347
Total Current Liabilities  (as reported)83,059
Total Current Liabilities  (calculated)83,059
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock155,833
Retained Earnings -1,053,922
Accumulated Other Comprehensive Income 454
Other Stockholders Equity 1,353,408
Total Stockholder Equity (as reported)455,773
Total Stockholder Equity (calculated)455,773
+/-0
Other
Capital Stock155,833
Cash and Short Term Investments 526,580
Common Stock Shares Outstanding 60,697
Liabilities and Stockholders Equity 538,832
Net Debt -81,659
Net Invested Capital 299,953
Net Working Capital 455,773



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
2,930
44,350
45,642
42,103
38,654
35,543
77,301
72,061
67,063
61,267
67,144
60,502
56,077
49,786
79,713
71,277
77,739
128,519
117,494
100,096
83,183
64,781
172,911
155,631
161,618
163,614
146,982
129,061
109,926
83,170
106,707
91,566
71,144
52,453
243,529
207,265
341,859
487,602
436,067
421,089
608,484
569,778
538,832
538,832569,778608,484421,089436,067487,602341,859207,265243,52952,45371,14491,566106,70783,170109,926129,061146,982163,614161,618155,631172,91164,78183,183100,096117,494128,51977,73971,27779,71349,78656,07760,50267,14461,26767,06372,06177,30135,54338,65442,10345,64244,3502,930000
   > Total Current Assets 
0
0
0
2,730
44,095
45,375
41,728
38,286
35,204
76,906
71,679
66,424
60,305
66,203
59,519
54,991
48,843
78,888
70,382
76,671
126,818
109,935
92,630
74,505
54,265
161,866
144,399
149,789
151,412
134,368
117,514
98,891
72,596
96,646
82,219
62,258
44,375
239,886
205,949
341,528
487,273
435,736
421,079
608,474
569,768
538,832
538,832569,768608,474421,079435,736487,273341,528205,949239,88644,37562,25882,21996,64672,59698,891117,514134,368151,412149,789144,399161,86654,26574,50592,630109,935126,81876,67170,38278,88848,84354,99159,51966,20360,30566,42471,67976,90635,20438,28641,72845,37544,0952,730000
       Cash And Cash Equivalents 
0
0
0
2,616
43,791
39,081
30,840
29,294
24,016
70,628
49,544
47,748
16,801
26,934
13,162
12,817
10,760
20,579
14,532
22,461
85,645
25,430
24,545
19,253
12,594
65,713
54,223
90,095
80,231
34,765
24,665
15,142
14,637
37,470
38,989
34,863
35,243
235,358
90,592
188,893
227,552
45,144
71,580
89,423
48,493
81,659
81,65948,49389,42371,58045,144227,552188,89390,592235,35835,24334,86338,98937,47014,63715,14224,66534,76580,23190,09554,22365,71312,59419,25324,54525,43085,64522,46114,53220,57910,76012,81713,16226,93416,80147,74849,54470,62824,01629,29430,84039,08143,7912,616000
       Short-term Investments 
0
0
0
0
0
0
3,302
3,768
4,970
2,947
18,491
15,754
41,067
36,459
42,587
37,482
32,715
51,614
50,203
52,052
38,070
80,111
64,155
52,696
36,398
92,017
85,753
56,178
46,429
93,813
87,763
77,986
52,088
51,080
34,687
20,848
3,235
0
113,007
150,384
257,089
380,851
342,647
513,665
516,327
444,921
444,921516,327513,665342,647380,851257,089150,384113,00703,23520,84834,68751,08052,08877,98687,76393,81346,42956,17885,75392,01736,39852,69664,15580,11138,07052,05250,20351,61432,71537,48242,58736,45941,06715,75418,4912,9474,9703,7683,302000000
       Net Receivables 
0
0
0
0
0
3,427
4,235
1,697
1,618
1,625
1,571
1,215
981
1,213
2,452
3,078
3,373
4,281
2,422
0
0
0
0
0
0
0
0
0
21,500
0
0
815
1,012
479
669
375
330
1,646
163
0
0
0
0
0
0
3,500
3,5000000001631,6463303756694791,0128150021,5000000000002,4224,2813,3733,0782,4521,2139811,2151,5711,6251,6181,6974,2353,42700000
       Other Current Assets 
0
0
0
114
304
2,867
3,351
3,527
4,600
1,706
2,073
1,707
1,456
1,597
1,318
1,614
1,995
2,414
3,225
2,158
3,103
4,394
3,930
2,556
5,273
4,136
4,423
3,516
3,252
5,790
5,086
4,948
4,859
7,617
7,874
6,172
5,567
2,882
2,187
2,251
2,632
9,741
6,852
5,386
4,948
8,752
8,7524,9485,3866,8529,7412,6322,2512,1872,8825,5676,1727,8747,6174,8594,9485,0865,7903,2523,5164,4234,1365,2732,5563,9304,3943,1032,1583,2252,4141,9951,6141,3181,5971,4561,7072,0731,7064,6003,5273,3512,867304114000
   > Long-term Assets 
0
0
0
200
255
267
375
368
339
395
382
639
962
941
983
1,086
943
825
895
1,068
1,701
7,559
7,466
8,678
10,516
11,045
11,232
11,829
12,202
12,614
11,547
11,035
10,574
10,061
9,347
8,886
8,078
3,643
1,316
331
329
331
10
10
10
0
01010103313293311,3163,6438,0788,8869,34710,06110,57411,03511,54712,61412,20211,82911,23211,04510,5168,6787,4667,5591,7011,0688958259431,086983941962639382395339368375267255200000
       Property Plant Equipment 
0
0
0
162
217
229
337
348
321
377
342
599
822
802
844
854
810
776
846
1,018
952
5,939
5,852
7,111
8,956
9,453
9,610
9,872
9,641
9,220
8,813
9,153
7,946
7,505
7,069
7,247
6,690
2,316
0
0
0
0
0
0
0
0
000000002,3166,6907,2477,0697,5057,9469,1538,8139,2209,6419,8729,6109,4538,9567,1115,8525,9399521,018846776810854844802822599342377321348337229217162000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
1,058
1,230
2,738
2,451
2,550
3,842
3,377
3,863
4,097
4,084
4,540
4,994
5,740
5,866
6,266
7,596
10,311
12,230
17,879
20,301
23,102
21,976
20,653
19,357
21,786
39,859
27,958
26,980
25,985
21,513
22,550
24,011
20,839
18,801
450,898
452,667
157,843
335,333
61,682
93,699
90,680
87,168
83,059
83,05987,16890,68093,69961,682335,333157,843452,667450,89818,80120,83924,01122,55021,51325,98526,98027,95839,85921,78619,35720,65321,97623,10220,30117,87912,23010,3117,5966,2665,8665,7404,9944,5404,0844,0973,8633,3773,8422,5502,4512,7381,2301,058000
   > Total Current Liabilities 
0
0
0
1,058
1,188
2,701
2,419
2,523
3,820
3,361
3,837
3,965
3,957
4,418
4,877
5,629
5,765
6,175
7,515
10,239
11,806
13,019
15,396
18,359
17,138
15,890
14,349
16,443
32,370
20,604
20,428
20,144
16,298
15,862
17,678
14,656
12,637
232,234
44,872
31,978
42,818
22,122
57,539
54,060
70,678
83,059
83,05970,67854,06057,53922,12242,81831,97844,872232,23412,63714,65617,67815,86216,29820,14420,42820,60432,37016,44314,34915,89017,13818,35915,39613,01911,80610,2397,5156,1755,7655,6294,8774,4183,9573,9653,8373,3613,8202,5232,4192,7011,1881,058000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
317
328
289
351
293
228
341
319
315
412
415
436
457
477
587
625
608
4,331
0
0
0
0
0
0
0
0
000000004,33160862558747745743641541231531934122829335128932831700000000000000000000
       Accounts payable 
0
0
0
345
290
1,109
562
176
509
348
523
168
267
634
615
389
763
952
1,077
663
3,223
2,724
2,431
3,154
3,618
4,151
2,295
2,254
1,878
2,221
1,863
3,319
2,981
1,958
4,178
677
2,062
2,854
1,678
896
3,106
3,231
5,165
666
3,689
3,712
3,7123,6896665,1653,2313,1068961,6782,8542,0626774,1781,9582,9813,3191,8632,2211,8782,2542,2954,1513,6183,1542,4312,7243,2236631,0779527633896156342671685233485091765621,109290345000
       Other Current Liabilities 
0
0
0
713
898
1,592
1,857
2,347
3,311
3,013
3,133
3,726
3,639
3,713
4,212
5,220
5,002
5,223
6,438
9,576
8,266
9,967
12,676
14,854
13,227
11,511
11,713
13,870
10,951
12,441
13,359
14,030
10,791
13,136
12,408
12,837
9,665
224,119
43,194
31,082
39,712
18,891
52,374
53,394
66,989
79,347
79,34766,98953,39452,37418,89139,71231,08243,194224,1199,66512,83712,40813,13610,79114,03013,35912,44110,95113,87011,71311,51113,22714,85412,6769,9678,2669,5766,4385,2235,0025,2204,2123,7133,6393,7263,1333,0133,3112,3471,8571,592898713000
   > Long-term Liabilities 
0
0
0
0
42
37
32
27
22
16
26
132
127
122
117
111
101
91
81
72
424
4,860
4,905
4,743
4,838
4,763
5,008
5,343
7,489
7,354
6,552
5,841
5,215
6,688
6,333
6,183
6,164
218,664
407,795
125,865
292,515
39,560
36,160
36,620
16,490
0
016,49036,62036,16039,560292,515125,865407,795218,6646,1646,1836,3336,6885,2155,8416,5527,3547,4895,3435,0084,7634,8384,7434,9054,860424728191101111117122127132261622273237420000
> Total Stockholder Equity
0
0
0
1,872
43,120
42,904
39,652
36,104
31,701
73,924
68,198
62,966
57,183
62,604
55,508
50,337
43,920
73,447
63,681
67,428
116,289
99,615
79,795
60,081
42,805
152,258
136,274
139,832
123,755
119,024
102,081
83,941
61,657
84,157
67,555
50,305
33,652
-207,369
-245,402
184,016
152,269
374,385
327,390
517,804
482,610
455,773
455,773482,610517,804327,390374,385152,269184,016-245,402-207,36933,65250,30567,55584,15761,65783,941102,081119,024123,755139,832136,274152,25842,80560,08179,79599,615116,28967,42863,68173,44743,92050,33755,50862,60457,18362,96668,19873,92431,70136,10439,65242,90443,1201,872000
   Common Stock
0
0
0
811
1
1
1
0
0
1
1
1
1
2
2
2
2
2
2
2
3
3
3
3
3
5
5
5
5
5
5
5
5
6
6
6
6
6
7
10
10
12
12
13
13
155,833
155,83313131212101076666655555555333332222222111100111811000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
2
-1
3
1
3
-4
-37
-29
-32
-102
-98
-56
-33
-27
13
67
78
51
-134
39
20
11
25
11
2
-20
-153
-220
-184
-48
-6
11
-132
302
-363
-553
1,457
180
682
454
4546821801,457-553-363302-13211-6-48-184-220-153-2021125112039-13451786713-27-33-56-98-102-32-29-37-4313-12000000
   Capital Surplus 0000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
620
766
930
1,373
1,513
107,478
107,988
108,246
108,743
120,787
121,568
122,950
124,648
163,547
165,675
184,314
250,301
251,592
253,334
255,142
256,779
387,475
389,543
415,824
417,951
420,064
423,437
425,765
428,050
472,939
474,535
475,971
477,698
453,741
455,957
763,191
775,966
1,066,214
1,095,632
1,343,618
1,343,300
1,353,408
1,353,4081,343,3001,343,6181,095,6321,066,214775,966763,191455,957453,741477,698475,971474,535472,939428,050425,765423,437420,064417,951415,824389,543387,475256,779255,142253,334251,592250,301184,314165,675163,547124,648122,950121,568120,787108,743108,246107,988107,4781,5131,3739307666200000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue886
Cost of Revenue-964
Gross Profit886-78
 
Operating Income (+$)
Gross Profit886
Operating Expense-208,566
Operating Income-208,566-207,680
 
Operating Expense (+$)
Research Development162,790
Selling General Administrative45,776
Selling And Marketing Expenses0
Operating Expense208,566208,566
 
Net Interest Income (+$)
Interest Income21,312
Interest Expense-0
Other Finance Cost-0
Net Interest Income21,312
 
Pretax Income (+$)
Operating Income-208,566
Net Interest Income21,312
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-207,967-209,165
EBIT - interestExpense = -128,564
-207,967
-208,018
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-128,564-207,967
Earnings Before Interest and Taxes (EBITDA)-207,967
 
After tax Income (+$)
Income Before Tax-207,967
Tax Provision-51
Net Income From Continuing Ops-208,018-208,018
Net Income-208,018
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses243,189
Total Other Income/Expenses Net599-21,312
 

Technical Analysis of Spyre
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Spyre. The general trend of Spyre is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Spyre's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Spyre Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Spyre Therapeutics Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 20.07 < 20.25 < 20.33.

The bearish price targets are: 21.03 > 19.50 > 19.20.

Know someone who trades $SYRE? Share this with them.πŸ‘‡

Spyre Therapeutics Inc. Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Spyre Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Spyre Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Spyre Therapeutics Inc.. The current macd is 0.49852701.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Spyre price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Spyre. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Spyre price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Spyre Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartSpyre Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Spyre Therapeutics Inc.. The current adx is 16.85.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Spyre shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Spyre Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Spyre Therapeutics Inc.. The current sar is 15.37.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Spyre Therapeutics Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Spyre Therapeutics Inc.. The current rsi is 72.85. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Spyre Therapeutics Inc. Daily Relative Strength Index (RSI) ChartSpyre Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Spyre Therapeutics Inc.. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Spyre price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Spyre Therapeutics Inc. Daily Stochastic Oscillator ChartSpyre Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Spyre Therapeutics Inc.. The current cci is 373.04.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Spyre Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartSpyre Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Spyre Therapeutics Inc.. The current cmo is 57.44.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Spyre Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartSpyre Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Spyre Therapeutics Inc.. The current willr is -4.85367595.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Spyre Therapeutics Inc. Daily Williams %R ChartSpyre Therapeutics Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Spyre Therapeutics Inc..

Spyre Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Spyre Therapeutics Inc.. The current atr is 1.13804091.

Spyre Therapeutics Inc. Daily Average True Range (ATR) ChartSpyre Therapeutics Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Spyre Therapeutics Inc.. The current obv is 14,118,914.

Spyre Therapeutics Inc. Daily On-Balance Volume (OBV) ChartSpyre Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Spyre Therapeutics Inc.. The current mfi is 75.48.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Spyre Therapeutics Inc. Daily Money Flow Index (MFI) ChartSpyre Therapeutics Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Spyre Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-08-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-09-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Spyre Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Spyre Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5072.848
Ma 20Greater thanMa 5016.186
Ma 50Greater thanMa 10016.388
Ma 100Greater thanMa 20016.248
OpenGreater thanClose17.660
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Spyre with someone you think should read this too:
  • Are you bullish or bearish on Spyre? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Spyre? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Spyre Therapeutics Inc.

I send you an email if I find something interesting about Spyre Therapeutics Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Spyre Therapeutics Inc..

Receive notifications about Spyre Therapeutics Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.